CATX

Perspective Therapeutics to Participate at Upcoming April Investor Conferences

Retrieved on: 
星期一, 四月 8, 2024
Jefferies, Cancer, Conference, CATX, Radiopharmaceutical

SEATTLE, April 08, 2024 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or “the Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout the body, today announced it will participate in two investor conferences in April.

Key Points: 
  • SEATTLE, April 08, 2024 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or “the Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout the body, today announced it will participate in two investor conferences in April.
  • Thijs Spoor, Chief Executive Officer, will be participating in a panel discussion titled Radiopharmaceuticals: Energizing Disruption in Therapeutics, at the Goldman Sachs Third Annual Healthruption Conference, on April 9, 2024 at 2:40 p.m.
  • Management will be available for one-on-one investor meetings at the conference.
  • A replay of the Jefferies presentation will be archived for 90 days and available through the Investors page on the Perspective website.

Perspective Therapeutics Provides Recent Business Highlights and Reports Fiscal Year 2023 Financial Results

Retrieved on: 
星期四, 三月 28, 2024
Stony Brook University, University, Adenocarcinoma, PRRT, Patient, Mayo Clinic, Sale, Bristol Myers Squibb, Society, IND, European Journal, Therapy, SPECT, Melanoma, Research, MC1R, Fortis Healthcare, SNMMI, Cohort, Trial of the century, Radiopharmaceutical, Cancer, Nivolumab, Safety, CATX, PSMA, Food, LNTH, BMY, IIT, Prostate cancer, Nuclear medicine, EANM, NETS, Institute of technology, Diagnosis, Glomus tumor, PET, Prostate, Small business, Bangladesh Technical Education Board, Molecular imaging, Pharmaceutical industry

SEATTLE, March 28, 2024 (GLOBE NEWSWIRE) -- Perspective, Therapeutics, Inc. (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout the body, today provided a business update and announced fiscal year 2023 financial results for the period ended December 31, 2023.

Key Points: 
  • SEATTLE, March 28, 2024 (GLOBE NEWSWIRE) -- Perspective, Therapeutics, Inc. (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout the body, today provided a business update and announced fiscal year 2023 financial results for the period ended December 31, 2023.
  • “We made tremendous progress during 2023 in building a fully integrated radiopharmaceuticals company dedicated to advancing potentially best- or first-in-class alpha-particle therapies,” said Thijs Spoor, Perspective Therapeutics' CEO.
  • Preliminary results from Cohorts 1 and 2 of the Phase 1/2a trial are expected in the third quarter 2024.
  • In January 2024, Perspective Therapeutics entered into strategic agreements with Lantheus Holdings, Inc. and its affiliates (“Lantheus”) (NASDAQ: LNTH).

Perspective Therapeutics Announces Clinical Collaboration Agreement with Bristol Myers Squibb to Evaluate [(212)Pb]VMT01 in Combination with Nivolumab in MC1R-Positive Metastatic Melanoma

Retrieved on: 
星期一, 三月 18, 2024
MC1R, BMY, Patient, Bristol Myers Squibb, Perspective, Therapy, Cancer, Nivolumab, Safety, Melanoma, CATX, PD-1, Pharmaceutical industry

This combination study is an amendment to the Company’s ongoing Phase1/2a study of [212Pb]VMT01 in patients with metastatic melanoma.

Key Points: 
  • This combination study is an amendment to the Company’s ongoing Phase1/2a study of [212Pb]VMT01 in patients with metastatic melanoma.
  • The study has completed enrollment in the first cohort and has commenced dosing in the second cohort.
  • Under the terms of the collaboration, Perspective will sponsor and fund the combination study and Bristol Myers Squibb will provide nivolumab for use in the study.
  • “We see great potential for synergistic treatment effect with our novel, systemically delivered, MC1R-targeted alpha-particle radioligand therapy, [212Pb]VMT01, in combination with nivolumab, a well-studied immunotherapy,” commented Markus Puhlmann, Chief Medical Officer of Perspective Therapeutics.

Perspective Therapeutics to Host In-Person and Virtual Analyst Day to Discuss Targeted Alpha-Particle Radiotherapy for Cancer on March 18, 2024

Retrieved on: 
星期一, 三月 11, 2024
Mallinckrodt Institute of Radiology, Neoplasm, Toxicity, Cancer, Perspective, Radiation, CATX, Peptide, Therapy

SEATTLE, March 11, 2024 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. ("Perspective" or "the Company") (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout the body, today announced that it will host an in-person and virtual analyst day at the New York Stock Exchange on Monday, March 18, 2024 at 10:00 AM ET.

Key Points: 
  • SEATTLE, March 11, 2024 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. ("Perspective" or "the Company") (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout the body, today announced that it will host an in-person and virtual analyst day at the New York Stock Exchange on Monday, March 18, 2024 at 10:00 AM ET.
  • To register, click here .
  • In addition, the Company’s management will discuss its next radiotherapy compound in development and provide an overview of its promising novel pretargeting technology.
  • A live question and answer session will follow the formal presentations.

Perspective Therapeutics Acquires CGMP-Compliant Manufacturing Facility

Retrieved on: 
星期二, 三月 5, 2024
Good manufacturing practice, Acquisition, Toxicity, Code, Neoplasm, Part, Cancer, CFR, CATX, LNTH, Therapy, TAT, Radiopharmaceutical, Patient, Clinical trial, Half-life, CGMP, Pharmaceutical industry

As a cGMP compliant facility, Perspective intends to utilize the facility to manufacture clinical supply of high quality 203Pb-labeled tumor-specific peptides to visualize and diagnose tumors, and 212Pb-labeled radiopharmaceuticals to treat target tumors with targeted alpha therapies (TAT).

Key Points: 
  • As a cGMP compliant facility, Perspective intends to utilize the facility to manufacture clinical supply of high quality 203Pb-labeled tumor-specific peptides to visualize and diagnose tumors, and 212Pb-labeled radiopharmaceuticals to treat target tumors with targeted alpha therapies (TAT).
  • The facility acquisition is part of a series of strategic agreements with Lantheus that Perspective announced on January 9, 2024, which included an initial equity investment in Perspective.
  • “We look forward to welcoming the exceptional talent at this facility and integrating them into our team,” said Shane Cobb, Executive Vice President of Operations, Perspective Therapeutics.
  • This is a significant milestone for Perspective as we build upon the progress we have made in establishing clinical manufacturing.”
    “We are thrilled to expand our manufacturing and supply chain infrastructure to include this facility capable of operating in compliance with Parts 212 and 211,” said Thijs Spoor, Chief Executive Officer, Perspective Therapeutics.

Perspective Therapeutics Announces $87.4 Million Private Placement

Retrieved on: 
星期一, 三月 4, 2024
Prospectus, Investment, Cancer, Sale, CATX, Therapy, Public expenditure, Oppenheimer Holdings, Research, Security (finance)

The private placement is expected to close on March 6, 2024, subject to the satisfaction of customary closing conditions.

Key Points: 
  • The private placement is expected to close on March 6, 2024, subject to the satisfaction of customary closing conditions.
  • Oppenheimer & Co. is acting as lead placement agent for the private placement.
  • B. Riley Securities is acting as a placement agent, and JonesTrading Institutional Services LLC and LifeSci Capital are acting as co-placement agents for the private placement.
  • The Company has agreed to file a registration statement with the U.S. Securities and Exchange Commission (the “SEC”) registering the resale of the shares of common stock issued in the private placement within a specified period of time after the closing of the private placement.

Perspective Therapeutics to Participate at Upcoming Investor Conferences

Retrieved on: 
星期一, 二月 26, 2024
Radiopharmaceutical, Cancer, Isotope, Therapy, Fireside chats, CATX, Security (finance)

SEATTLE, Feb. 26, 2024 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or “the Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout the body, today announced that management will participate at upcoming discussions and investor conferences in February and March, 2024.

Key Points: 
  • SEATTLE, Feb. 26, 2024 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or “the Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout the body, today announced that management will participate at upcoming discussions and investor conferences in February and March, 2024.
  • Fireside Chat with JonesResearch – February 28, virtual
    Please RSVP to your JonesResearch representative.
  • Panel: Good But Not The Best Yet: Drug Designs to Beat Standard of Care
    Panel: Enough with Lu177 and Ac225?
  • Other Isotopes in Store for Radiopharma
    Please RSVP to your B. Riley Securities representative, additional details will be provided upon registration.

Perspective Therapeutics to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference

Retrieved on: 
星期一, 二月 12, 2024
Cancer, Therapy, Conference, CATX

SEATTLE, Feb. 12, 2024 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or “the Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout the body, today announced that Thijs Spoor, Chief Executive Officer, will present virtually at the Oppenheimer 34th Annual Healthcare Life Sciences Conference on Wednesday, February 14, 2024, at 11:20 a.m.

Key Points: 
  • SEATTLE, Feb. 12, 2024 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or “the Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout the body, today announced that Thijs Spoor, Chief Executive Officer, will present virtually at the Oppenheimer 34th Annual Healthcare Life Sciences Conference on Wednesday, February 14, 2024, at 11:20 a.m.
  • ET.
  • Management will also be available for one-on-one meetings.
  • The live webcast can be accessed at https://wsw.com/webcast/oppenheimer33/catx/2781216 and replays will be available on the Company's website for 90 days.

Perspective Therapeutics Introduces “Pre-Targeting” Theranostic Technology Platform

Retrieved on: 
星期四, 二月 1, 2024
Stony Brook University, Toxicity, National Cancer Institute, Research, Riitta Jallinoja, NIH, CB7, CATX, Patient, Safety, Diagnosis, Adma, CEA, Ligand, Therapy, Radiation, Journal, Assistant professor, Cancer, Neoplasm, Radiology, Bangladesh Technical Education Board, Radioactive decay, Nuclear medicine, Vaccine

This antibody is chemically modified to include the CB7 chemical entity and accumulates over time at the tumor site.

Key Points: 
  • This antibody is chemically modified to include the CB7 chemical entity and accumulates over time at the tumor site.
  • Then, a radionuclide held tightly by Perspective’s proprietary chelator attached to an Adma group is administered.
  • The research conducted at Stony Brook University refines the understanding of the potential of the proprietary CB7-Adma pre-targeting platform for image-guided radionuclide therapy for oncology.
  • The technology was first described by Stony Brook University researchers, Jacob L. Houghton, Ph.D. and Vilma I.J.

Perspective Therapeutics Announces Closing of $69.0 Million Public Offering and $20.8 Million Private Placement

Retrieved on: 
星期一, 一月 22, 2024
Therapy, Research, Perspective, Prospectus, CATX, Form, Public expenditure, Sale, Cancer, Suite, Investment, Broad Street, Telephone, Attention, Exercise, Security (finance), Oppenheimer Holdings

All of the shares of common stock and pre-funded warrants sold in the public offering were sold by Perspective.

Key Points: 
  • All of the shares of common stock and pre-funded warrants sold in the public offering were sold by Perspective.
  • Gross proceeds to Perspective in the public offering were approximately $69.0 million, before underwriting discounts and commissions and estimated expenses of the public offering.
  • The aggregate gross proceeds from the public offering and the concurrent private placement were approximately $89.8 million, before underwriting discounts and commissions and other offering expenses payable by Perspective.
  • The securities described above in the public offering were offered by Perspective pursuant to a shelf registration statement on Form S-3 (File No.